Skip to main content
main-content

Nephropathy

News

05-01-2021 | Heart failure | News

Support for fluid reduction mechanism underlying SGLT2 inhibitor cardiorenal benefits

The SGLT2 inhibitor empagliflozin reduces estimated extracellular volume and plasma volume in patients who have heart failure with reduced ejection fraction, shows a randomized trial.

18-12-2020 | Dapagliflozin | Highlight | News

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

17-12-2020 | Canagliflozin | News

Model demonstrates cost-effectiveness of canagliflozin in type 2 diabetes

Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.

Read more

Opinion

06-08-2019 | SGLT2 inhibitors | Editorial | Article

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity.

08-05-2017 | Metformin | Editorial | Article

Metformin: What is new with this old medication?

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.

04-11-2016 | Clinical trial | Editorial | Article

My EASD 2016 Highlights: From Paleolithic diets to the artificial pancreas

Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.

Journal articles and book chapters

08-11-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

08-09-2018 | Nephropathy | Review | Article

Metabolic abnormalities in diabetes and kidney disease: Role of uremic toxins

Koppe L, Fouque D, Soulage CO. Curr Diab Rep 2018; 18: 97. doi: 10.1007/s11892-018-1064-7

15-08-2018 | Nephropathy | Review | Article

Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis

Iyengar R, Franzese J, Gianchandani R. Curr Diab Rep 2018; 18: 75. doi: 10.1007/s11892-018-1044-y

Case reports

Image Credits